While there were no observed differences at baseline between e-MDSCs from both the radiographic and biochemical responding groups, there was an observed trend for e-MDSCs to decrease slowly in responders but faster in non-responders, nearly reaching the healthy donor levels ( Table 2 B,C). 4.
← all excerpts
Phase II Trial of Sipuleucel-T and Stereotactic Ablative Body Radiation for Patients with Metastatic Castrate-Resistant Prostate Cancer.
1
—
—